• THZ1: Covalent CDK7 Inhibitor Workflows in T-ALL Research

  2026-06-22

  THZ1 stands out as a covalent CDK7 inhibitor with nanomolar potency and unique selectivity for transcriptional regulation in cancer biology. This guide translates bench research and reference study insights into actionable protocols, troubleshooting strategies, and advanced applications for T-ALL and beyond.

• GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor in Redox R

  2026-06-22

  GKT137831 empowers oxidative stress researchers with targeted, reproducible inhibition of Nox1 and Nox4, yielding precise control over ROS pathways in disease models. Its robust solubility and validated protocols streamline both cell-based and in vivo studies, advancing applications from vascular remodeling to fibrosis.

• Isoliensinine Modulates MAPK/NF-κB to Attenuate Neuroinflamm

  2026-06-21

  This study demonstrates that isoliensinine significantly reduces LPS-induced neuroinflammation in microglia by inhibiting the MAPK/NF-κB signaling pathway and mitigating oxidative stress and mitochondrial dysfunction. The findings provide mechanistic insights relevant for Alzheimer’s research and highlight actionable targets for neuroprotection.

• PEGylation Improves Targeted mRNA Delivery Stability and Eff

  2026-06-20

  Folda et al. demonstrate that PEGylation of LAF–xenopeptide mRNA polyplexes enhances colloidal stability and enables ligand-directed targeting without compromising biosafety. Their work clarifies how PEG content and surface functionalization can optimize mRNA delivery systems for therapeutic and research applications.

• Lipid Peroxidation (MDA) Assay Kit: Precision in Ferroptosis

  2026-06-19

  Discover how the Lipid Peroxidation (MDA) Assay Kit enables robust quantification of malondialdehyde, a key biomarker of oxidative stress, and uniquely advances mechanistic studies of ferroptosis and autophagy. This in-depth article explores assay design, protocol optimization, and translational value for advanced biomedical research.

• VX-661 and Calnexin: Precision CFTR Rescue for Translational

  2026-06-19

  This thought-leadership article explores the mechanistic and strategic landscape of VX-661 (F508del CFTR corrector) in cystic fibrosis research, focusing on the interplay between calnexin-dependent proteostasis and pharmacological rescue. Drawing on recent deep mutational scanning studies, it provides actionable insights for translational researchers aiming to optimize experimental workflows and personalize CFTR modulator strategies. The discussion goes beyond standard product guides, highlighting emerging challenges and future directions in the field.

• Carvedilol in β-Adrenergic Receptor Research: Applied Workfl

  2026-06-18

  Leverage Carvedilol’s unique dual antagonism and antioxidant properties for cutting-edge β-adrenergic and α1-adrenergic receptor research. This guide delivers actionable workflows, troubleshooting strategies, and data-driven insights to refine your cardiovascular, vascular, and hematopoietic assays.

• Structural Insights into HCAR3–Agonist Interactions for Lipi

  2026-06-18

  Ye et al. (2025) provide high-resolution cryo-EM structures of HCAR3 bound to selective agonists, including Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid), revealing the molecular basis for ligand specificity and functional selectivity between HCAR3 and HCAR2. These findings lay the groundwork for rational drug design targeting dyslipidemia and metabolic disorders while minimizing off-target effects.

• Interpretable Machine Learning Reveals Ferroptosis Genes in

  2026-06-17

  This study advances the understanding of vascular calcification by leveraging interpretable machine learning to identify ferroptosis-related genes as key predictive factors. Its rigorous integration of SHAP and LIME with experimental validation enhances both mechanistic insight and diagnostic accuracy, informing future research in oxidative lipid damage and disease modeling.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-17

  Anlotinib hydrochloride from APExBIO empowers cancer researchers with nanomolar potency and precise inhibition of VEGFR2, PDGFRβ, and FGFR1. Discover how its robust anti-angiogenic effects, low cytotoxicity, and validated protocols streamline endothelial cell and tumor microenvironment assays.

• Rapakinin Induces Vasorelaxation via PGI2–IP and CCK1 Recept

  2026-06-16

  The referenced study discovers that rapakinin, a rapeseed-derived tripeptide, induces vasorelaxation in hypertensive rat arteries predominantly through the prostaglandin I2 (PGI2) IP receptor and downstream CCK1 receptor, rather than nitric oxide-mediated pathways. These findings refine mechanistic understanding of anti-hypertensive peptide action and provide a framework for designing cardiovascular disease models beyond classic NOS inhibition.

• U-73122: Precision PLC-β2 Inhibition for Translational Resea

  2026-06-16

  Explore how U-73122, a selective phospholipase C inhibitor from APExBIO, is transforming translational research in cancer and inflammation. This article provides mechanistic insights, experimental protocols, and strategic guidance, drawing on the latest evidence—including QPRT-driven breast cancer invasion—while mapping emerging opportunities in PLC signaling pathway modulation.

• BET Bromodomain Inhibition: Translating Epigenetics to Oncol

  2026-06-15

  Unlocking the full potential of BET inhibitors like I-BET151 (GSK1210151A) requires more than protocol adherence—it demands mechanistic fluency and strategic vision. This article synthesizes landmark findings on BET protein biology and super-enhancer regulation with actionable guidance for translational researchers, contextualizing I-BET151 within emerging paradigms such as disulfidptosis and MLL-fusion leukemia. Drawing from recent high-impact studies, we chart a forward-looking path for integrating BET inhibition into advanced cancer models, highlighting experimental nuances and clinical promise.

• Lipid Scrambling, Ferroptosis, and Tumor Immune Rejection: M

  2026-06-15

  Yang et al. uncover TMEM16F-mediated lipid scrambling as a critical suppressor of ferroptosis at the plasma membrane, showing that its inhibition sensitizes tumor cells to ferroptosis and enhances immune rejection. This mechanistic advance reveals new opportunities for cancer therapy by targeting membrane remodeling processes during cell death.

• Phosbind Biotin LC: Sequence-Independent Phosphorylation Det

  2026-06-14

  Phosbind Biotin LC addresses the detection of phosphorylated proteins on PVDF membranes in Western Blot workflows, especially when sequence-specific phospho-antibodies are unavailable or insufficient. It should not be used with aqueous-only protocols or for long-term storage of working solutions.

8527 records 9/569 page Previous Next First page 上5页 678910 下5页 Last page